E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Untreated, operable ER+, HER2-negative primary breast cancer. |
|
E.1.1.1 | Medical condition in easily understood language |
Untreated, operable breast cancer. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10057654 |
E.1.2 | Term | Breast cancer female |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To determine whether adding immune-modulatory agents to atezolizumab increases the probability of an immune response over atezolizumab alone in patients with operable ER+ breast cancer. |
|
E.2.2 | Secondary objectives of the trial |
• Status and changes of the biomarkers listed below in pre- and end-of treatment tumour and/or blood samples: Immunephenotyping, CD8, PD-L1, MHC-I,immune infiltrates (IFNg gene signature expression).
• Percentage change in Ki67 expression and caspase-3 expression between pre- and end of study-treatment tumour biopsies.
• Incidence, nature and severity of adverse events with severity determined according to CTCAE v4.03.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Willing and able to provide written informed consent prior to study entry 2. Female ≥ 18 years of age 3. Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 1 4. Histologically confirmed operable primary breast cancer 5. Palpable breast tumour of any size, or tumour with an ultrasound / MRI size of ≥ 1 cm or mammogram 6. ER+ tumours defined as tumours with ≥1% of tumour cells positive for ER on IHC staining or an IHC score (Allred) of ≥ 3 7. HER2-negative tumours defined as 0, 1+ or 2+ intensity on IHC and no evidence of amplification of the HER2 gene on ISH. 8. Patients with either: (a) Luminal B breast cancer defined as: high Ki67 defined as ≥20% and /or histological grade 3 and / or Luminal B according to PAM50 assay OR (b) Non-Luminal B breast cancer 9. Adequate haematologic and end-organ function within 28 days prior to the first study treatment. 10. Patients of childbearing potential are eligible provided they have a negative serum or urine pregnancy test within 14 days of Day 1 Cycle 1 of study treatment, preferably as close to the first dose as possible. Patients must agree to use adequate contraception, defined as those methods with a failure rate of < 1 % per year, beginning 14 days before the first dose of study drug and for 6 months after the last dose of study drug. 11. Ability to comply with the protocol 12. Representative formalin-fixed paraffin embedded (FFPE) breast tumour samples with an associated pathology report that are determined to be available and sufficient for central testing OR tumour accessible for biopsy.
|
|
E.4 | Principal exclusion criteria |
1. Inflammatory breast cancer 2. Concurrent use of HRT. 3. Previous systemic or local treatment for the new primary breast cancer currently under investigation; prior treatment for previous breast cancer or other neoplasms is allowed as long as it was completed ≥1 year prior to Day 1 Cycle 1. 4. Previous systemic treatment for other neoplasms within 1 year prior to randomisation. 5.Patients with prior allogeneic stem cell or solid organ transplantation. 6. Prior treatment with CD137 agonists, AKT inhibitors, anti-CTLA-4, anti− PD-1, or anti−PD-L1 therapeutic antibody or pathway-targeting agents. 7.Patients must not have had oral or IV steroids for 14 days prior to study entry; the use of inhaled corticosteroids, physiologic replacement doses of glucocorticoids and mineralocorticoids is allowed. 8. Received therapeutic oral or intravenous antibiotics <14 days prior to randomisation. 9. Administration of a live, attenuated vaccine <28 days prior to randomisation, treatment, or within 5 months following the last dose of atezolizumab. 10. Treatment with systemic immunostimulatory agents <28days or five half-lives of the drug, whichever is shorter, prior to enrolment. 11. History of autoimmune disease. Patients with autoimmune-related hypothyroidism on a stable dose of thyroid replacement therapy may be eligible for the study following discussion with the medical monitor. 12. History of idiopathic pulmonary fibrosis, drug-induced pneumonitis, organizing pneumonia, or evidence of active pneumonitis on screening chest CT scan. 13. History of HIV infection 14. Known active hepatitis infection or hepatitis C. 15. Active tuberculosis 16. History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins 17. Known hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulation. 18. Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that, in the investigator’s opinion, gives reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug, may affect the interpretation of the results, render the patient at high risk from treatment complications or interferes with obtaining informed consent. 19. Psychological, familial, sociological or geographical conditions that do not permit compliance with the study protocol. 20. Concurrent treatment with other experimental drugs or participation in another clinical trial with therapeutic intent < 28 days prior to randomisation. 21. Pregnant and lactating female patients. 22. Major surgical procedure < 4 weeks prior to randomisation or anticipation of need for a major surgical procedure during the course of the study other than for diagnosis. 23. Malignancies other than breast cancer < 5 years prior to Cycle 1, Day 1, with the exception of those with a negligible risk of metastasis or death and treated with expected curative outcome 24. Severe infections < 28 days prior to enrolment in the study including but not limited to hospitalization for complications of infection, bacteraemia, or severe pneumonia. 25. Significant cardiovascular disease. 26. Evidence of bleeding diathesis or coagulopathy. 27. Inability to swallow medication or malabsorption condition that would alter the absorption of orally administered medications. 28. Clinically significant abnormalities of glucose metabolism 29. History of or active inflammatory bowel disease or active bowel inflammation. 30. Treatment with strong CYP3A inhibitors or strong CYP3A inducers within 2 weeks or 5 drug-elimination half-lives, whichever is longer, prior to initiation of study drug. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
2-fold increase in GzmB+ CD8+ T cell levels from baseline to end of treatment sample. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Samples collected pre-treatment and on completion of treatment. |
|
E.5.2 | Secondary end point(s) |
1. Status and changes of the biomarkers listed below in pre- and end-of treatment tumour and/or blood samples: Immunephenotyping, CD8, PD-L1, MHC-I, immune infiltrates (IFNg gene signature expression).
2. Percentage change in Ki67 expression and caspase-3 expression between pre- and end of study-treatment tumour biopsies.
3. Incidence, nature and severity of adverse events with severity determined according to CTCAE v4.03. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1. Samples collected pre-treatment and on completion of treatment.
2. Samples collected pre-treatment and on completion of treatment.
3. Consent to 30 days after after the last dose of Atezolizumab.
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 5 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 12 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Korea, Republic of |
Germany |
Spain |
United Kingdom |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of study is defined as last patient last data collection, which for the primary and secondary analysis is expected to occur within approximately 24 months after the last patient last visit to allow for the centralisation of tumour samples and T cell analysis. All translational research will be completed within 24 months of the LPLV. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 30 |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 30 |